Phase I/II Study of of MRTX1719 in Patients with Advanced Solid Tumors With MTAP Homozygous Deletion
The purpose of this phase I/II study is to evaluate the safety and tolerability of MRXTX19 in patients with solid tumors, including pancreatic cancer with a homozygous deletion of the MTAP gene.
Study ID: 1719-001
Trial Phase: Phase I/II
Trial Sponsor: Mirati Therapeutics Inc.
Therapies Used in This Trial: MRTX1719